ISR / Perspective Therapeutics Inc - Depositi SEC, Relazione annuale, dichiarazione di delega

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Engineering the Alpha Advantage in Targeted Oncology Unlocking New Treatment Options Across Solid Tumors: Optimizing the Entire System Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Optimizing Structural Chemistry: Choosing The Right Isotope Not All ²¹²Pb Programs Are Created Equal Advancing a Theranostic

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma • One new responder observed in the [212Pb]VMT01 3.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33407 PE

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Engineering the Alpha Advantage in Targeted Oncology Unlocking New Treatment Options Across Solid Tumors: Optimizing the Entire System Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Optimizing Structural Chemistry: Choosing The Right Isotope Not All ²¹²Pb Programs Are Created Equal Advancing a Theranostic

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results • Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability • Three clinical-stage oncology programs advancing across neuroendocrine tumors, melanoma and FAP-positive solid tumors with multiple clinical catalysts expected in 2026 ac

Engineering the Alpha Advantage in Targeted Oncology

Agenda Engineering the Alpha Advantage in Targeted Oncology Optimizing the Entire System Expanding the Addressable Market Unlocking New Treatment Options Across Solid Tumors: Choosing The Right Isotope Optimizing Structural Chemistry: Not All ²¹²Pb Programs Are Created Equal Advancing a Theranostic Approach: A Decade of Deliberate, End-to-End Engineering Direct-to-Hospital Delivery through Integra

FORM 8-K Item 2.02 Results of Operations and Financial Condition. On May 4, 2026, Perspective Therapeutics, Inc. (the “Company”) posted to its website a presentation (the “Presentation”) containing slides presented at an analyst event hosted by the C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 04, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

-60 -40 -20 0 20 40 60 0 8 16 24 32 40 48 56 64 72 80 88 96 104 Percent change in sum of diameters from baseline 0 1 2 3 4 5 0 8 16 24 32 40 48 56 64 72 80 88 96 Study Week Creatinine (mg/dL) Safety Analysis Set Somatostatin receptor subtype 2 (SSTR2

-60 -40 -20 0 20 40 60 0 8 16 24 32 40 48 56 64 72 80 88 96 104 Percent change in sum of diameters from baseline 0 1 2 3 4 5 0 8 16 24 32 40 48 56 64 72 80 88 96 Study Week Creatinine (mg/dL) Safety Analysis Set Somatostatin receptor subtype 2 (SSTR2) is expressed in neuroendocrine tumors (NETs), and it is an important target for both diagnosis and therapy.

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting • Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025 • Safety update presented on all 64 patients who received at least one treatment and updated effi

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Proprietary Radioligand Platform Optimizes Therapeutic Index Proprietary Pb-Based Chelator Designed for Broader and Safer Use Lead-212: Optimal Isotope with Advantages Over Beta a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Proprietary Radioligand Platform Optimizes Therapeutic Index Proprietary Pb-Based Chelator Designed for Broader and Safer Use Lead-212: Optimal Isotope with Advantages Over Beta a

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 01, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

AMENDED & RESTATED EMPLOYMENT AGREEMENT

Exhibit 10.14 AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (“Agreement”) is made by and between Markus Puhlmann, M.D. (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as of November 3, 2025 (the “Effective Date”). WHEREAS, the Company is engaged in the business of developing innovative solu

AMENDED & RESTATED EMPLOYMENT AGREEMENT

Exhibit 10.13 AMENDED & RESTATED EMPLOYMENT AGREEMENT This Amended & Restated Employment Agreement (“Agreement”) is made by and between Johan Spoor (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as of November 3, 2025 (the “Effective Date”). WHEREAS, the Company is engaged in the business of developing innovative solutions for

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Proprietary Radioligand Platform Optimizes Therapeutic Index Proprietary Pb-Based Chelator Designed for Broader and Safer Use Lead-212: Optimal Isotope with Advantages Over Beta a

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-33407 Perspective

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

Subsidiaries of the Company

Exhibit 21.1 Subsidiaries of the Company California Alpha Targeted Therapies, LLC, a Delaware limited liability company Illinois Alpha Targeted Therapies, LLC, a Delaware limited liability company Isoray Medical, Inc., a Delaware corporation Perspective Therapeutics Pty Ltd, an Australian Company Texas Alpha Targeted Therapies, LLC, a Delaware limited liability company Viewpoint Molecular Targetin

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results • Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026 • VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patient

FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Perspective Therapeutics, Inc.

Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $500,000,000.

39,576,088 Shares of Common Stock Pre-Funded Warrants to Purchase 6,598,046 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-279692 Prospectus Supplement (To prospectus dated April 8, 2025) 39,576,088 Shares of Common Stock Pre-Funded Warrants to Purchase 6,598,046 Shares of Common Stock We are offering 39,576,088 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 6,598,046 shares of our common stock pursuant

For purposes of this Section ‎13, a “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the following: (i) a “covered entity” as that

Exhibit 1.1 Perspective Therapeutics, Inc. 39,576,088 Shares of Common Stock Pre-Funded Warrants to Purchase 6,598,046 Shares of Common Stock UNDERWRITING AGREEMENT Dated: February 2, 2026 Perspective Therapeutics, Inc. 39,576,088 Shares of Common Stock Pre-Funded Warrants to Purchase 6,598,046 Shares of Common Stock UNDERWRITING AGREEMENT February 2, 2026 Piper Sandler & Co. UBS Securities LLC as

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants SEATTLE – February 2, 2026 – Perspective Therapeutics, Inc.

FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: February [•], 2026 Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•], or its registered assigns (the “Hol

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Proprietary Radioligand Platform Optimizes Therapeutic Index Proprietary Pb-Based Chelator Designed for Broader and Safer Use Lead-212: Optimal Isotope with Advantages Over Beta a

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock

Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated February 2, 2026 Relating to Prospectus dated April 8, 2025 Registration Statement No.

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Proprietary Radioligand Platform Optimizes Therapeutic Index Proprietary Pb-Based Chelator Designed for Broader and Safer Use Lead-212: Optimal Isotope with Advantages Over Beta a

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Proprietary Radioligand Platform Optimizes Therapeutic Index Proprietary Pb-Based Chelator Designed for Broader and Safer Use Lead-212: Optimal Isotope with Advantages Over Beta a

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium • Updated interim results with an additional ~13 weeks of follow-up since the prior update • [212Pb]VMT-α-NET continues to be well-tolerated • Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.

Corporate Presentation

Corporate Presentation Developing the next generation of targeted therapies Higher potency payloads with cancer-specific targeting Upcoming data milestones Radiopharmaceutical therapy poised to revolutionize oncology treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s radiopha

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 01, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Corporate Presentation

Corporate Presentation Developing the next generation of targeted therapies Higher potency payloads with cancer-specific targeting Upcoming data milestones Radiopharmaceutical therapy poised to revolutionize oncology treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s radiopha

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Separation Agreement

Exhibit 10.2 Separation Agreement 1) People and Organizations Covered by this Agreement. In this Agreement, “you” means Juan Graham, your heirs, administrators and assigns. “We,” “us” “our” or the “Company” refers to Perspective Therapeutics, Inc., its predecessors, successors, assigns, divisions, affiliates, subsidiaries, and related corporations, and all past and present officers, directors, emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-3340

EMPLOYMENT AGREEMENT

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made by and between Joel Sendek (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as of September 4, 2025 (the “Effective Date”). WHEREAS, the Company is engaged in the business of developing innovative solutions for the treatment of cancers using medical

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results • Updated interim results from the Company’s [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetings • Enrolled eight patients into Cohort 3 (6.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Corporate Presentation November 2025 NYSE AMERICAN: CATX

Corporate Presentation November 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 • Updated interim results with an additional ~19 weeks of follow-up since the prior update • [212Pb]VMT-α-NET continues to be well-tolerated • Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on study • Initial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026 • Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET SEATTLE, October 20, 2025 – Perspective Therapeutics, Inc.

Investor CallESMO 2025 Presentation

Investor Call ESMO 2025 Presentation Developing the Next Generation of Targeted Therapies Neuroendocrine Tumors: VMT-⍺-NET Background and key takeaways Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors Confidence building in compelling overall clinical profile Next steps and concluding remarks [212Pb]VMT-α-NET was well-tolerated and demonstrated appreciable anti-tumor activity Ke

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 01, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investmen

Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer Distinguished career as a Wall Street analyst and significant CFO experience, bringing keen insights and understanding of finance and the life sciences investment landscape SEATTLE, September 04, 2025 - Perspective Therapeutics, Inc.

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors SEATTLE – September 03, 2025 – Perspective Therapeutics, Inc.

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33407 PER

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results • [212Pb]VMT-α-NET study update presented at the 2025 ASCO Annual Meeting, based on updated interim results from a Phase 1/2a study in neuroendocrine tumors.

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com

Corporate Presentation July 2025 NYSE AMERICAN: CATX

Corporate Presentation July 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi

[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2 positive tumors in the VMT-α-NET-T101 trial Stephen A. Graves1, Thorvardur R. Halfdanarson2, Richard L. Wahl3, Lowell Anthony4, Lilja B. Solnes5, Sam H. Mehr6, Ian R. Marsh7, Lucia Baratto

[212Pb]Pb-VMT-α-NET dosimetry in patients with advanced SSTR2 positive tumors in the VMT-α-NET-T101 trial Stephen A.

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting SEATTLE – June 21, 2025 – Perspective Therapeutics, Inc.

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial • [212Pb]VMT‑α‑NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 • Dosimetry sub-study analysis presented at the Society of Nuclear Medicine &

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting • Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.

Investor CallASCO 2025 Presentation

Investor Call ASCO 2025 Presentation Developing the Next Generation of Targeted Therapies Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Neuroendocrine Tumors: VMT-⍺-NET NETs Trials Interim safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Perspective Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33407 (Commission File Number) 41-1458152 (I.R.S. Employer Identification No.) 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 (Address

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33407 PE

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results • First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platform

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 01, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors SEATTLE – April 29, 2025 – Perspective Therapeutics, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.

As filed with the Securities and Exchange Commission on April 4, 2025

As filed with the Securities and Exchange Commission on April 4, 2025 Registration No.

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K/A

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001

Form of Perspective Therapeutics, Inc. Stock Option Agreement.

Exhibit 10.4 PERSPECTIVE THERAPEUTICS, INC. STOCK OPTION AGREEMENT Perspective Therapeutics, Inc. has granted to the individual (the “Participant”) named in the Notice of Grant of Stock Option (the “Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Common Stock upon the terms and conditions set forth in the Not

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Perspective Therapeutics, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

Subsidiaries of the Company.

Exhibit 21.1 Subsidiaries of the Company California Alpha Targeted Therapies, LLC, a Delaware limited liability company Illinois Alpha Targeted Therapies, LLC, a Delaware limited liability company Isoray Medical, Inc., a Delaware corporation Isoray International, LLC, a Washington limited liability company Perspective Therapeutics Pty Ltd, an Australian Company Texas Alpha Targeted Therapies, LLC,

Insider Trading Policy.

Exhibit 19.1 PERSPECTIVE THERAPEUTICS, INC. INSIDER TRADING POLICY Amended & Restated as of March 24, 2025 Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Perspective Therapeutics, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Co

Filing Fee Table, incorporated by reference to Exhibit 107 of the Registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form S-3 filed on March 26, 2025.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Perspective Therapeutics, Inc.

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results • On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one potential new medicine, all based on our next generation targeted radiopharmaceutical technology platform • Enrollment ongoing

As filed with the Securities and Exchange Commission on March 26, 2025

As filed with the Securities and Exchange Commission on March 26, 2025 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

As filed with the Securities and Exchange Commission on March 26, 2025

As filed with the Securities and Exchange Commission on March 26, 2025 Registration No.

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Higher Potency Payloads with Cancer-Specific Targeting Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Opti

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Perspective Therapeutics, Inc.

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-33407 Perspective

Executive Employment Agreement, effective as of January 6, 2025, by and between Perspective Therapeutics, Inc. and Juan Graham.

Exhibit 10.29 2401 Elliott Ave. - Suite 320 Seattle, WA 98121 Phone: (206) 676 - 0900 Toll Free: (877) 447 - 6729 https://perspectivetherapeutics.com EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made by and between Juan Graham (“Executive”) and Perspective Therapeutics, Inc., a Delaware corporation (the “Company”). This Agreement is effective as of January 6, 2025 (the “Effectiv

As filed with the Securities and Exchange Commission on March 26, 2025

As filed with the Securities and Exchange Commission on March 26, 2025 Registration No.

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma SEATTLE – March 17, 2025 – Perspective, Therapeutics, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

Corporate Presentation

Corporate Presentation Developing the Next Generation of Targeted Therapies Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT Perspective’s Innovative Platform Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window Proposed Mechani

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

JOINT FILING AGREEMENT

Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 03, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Corporate Presentation February 2025 NYSE AMERICAN: CATX

Corporate Presentation February 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium • Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.

Investor CallASCO-GI 2025 Presentation January 24, 2025 NYSE AMERICAN: CATX

Investor Call ASCO-GI 2025 Presentation January 24, 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Corporate Presentation January 2025 NYSE AMERICAN: CATX

Corporate Presentation January 2025 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 02, 2025 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Exhibit 99.1. Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer SEATTLE, WASHINGTON – January 6, 2025 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company’s Chi

Corporate Presentation December 2024 NYSE AMERICAN: CATX

Corporate Presentation December 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 03, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium • [212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.

Investor CallNANETS 2024 Presentation November 21, 2024 NYSE AMERICAN: CATX

Investor Call NANETS 2024 Presentation November 21, 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Corporate Presentation November 2024 NYSE AMERICAN: CATX

Corporate Presentation November 2024 NYSE AMERICAN: CATX This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

CATX / Perspective Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment

SC 13G/A 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46489V302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate

CATX / Perspective Therapeutics, Inc. / Avidity Partners Management LP Passive Investment

SC 13G 1 d1153051713-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 46489V302 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate

CATX / Perspective Therapeutics, Inc. / JANUS HENDERSON GROUP PLC - JANUS NEW Passive Investment

SC 13G 1 Perspective093024.txt JANUS NEW UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: PERSPECTIVE THERAPEUTICS INC Title of Class of Securities: Common Stock CUSIP Number: 46489V302 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designat

Separation Agreement between Perspective Therapeutics, Inc. and Mark Austin, dated August 26, 2024, incorporated by reference to Exhibit 10.1 of the Form 10-Q filed on November 12, 2024.

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]” HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Phone: (206) 676-0900 2401 Elliott Ave., Suite 320 Toll Free: (877) 447-6729 Seattle, WA 98121 https://perspectivetherapeutics.com August 19, 2024 Mark Austin [***] Re: Terms of S

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-3340

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results • Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in Oct

CATX / Perspective Therapeutics, Inc. / BlackRock, Inc. Passive Investment

SC 13G 1 us46489v3024110824.txt us46489v3024110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) PERSPECTIVE THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 46489V302 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropr

CATX / Perspective Therapeutics, Inc. / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.1 PERSPECTIVE THERAPEUTICS INC COMMON STOCK Cusip #46489V302 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #46489V302 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,494,391 Item 6: 0 Item 7: 9,496,225 Item 8: 0 Item 9: 9,496,225 It

CATX / Perspective Therapeutics, Inc. / FMR LLC Passive Investment

SCHEDULE 13G Amendment No.0 PERSPECTIVE THERAPEUTICS INC COMMON STOCK Cusip #46489V302 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #46489V302 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,504,150 Item 6: 0 Item 7: 5,504,822 Item 8: 0 Item 9: 5,504,822 It

CATX / Perspective Therapeutics, Inc. / BlackRock, Inc. Passive Investment

SC 13G 1 us46489v3024102424.txt us46489v3024102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) PERSPECTIVE THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 46489V302 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Perspective Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Exhibit 99.1 Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research • [212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi) • Prolonged progression-free survival and tu

Master Equipment and Services Agreement, dated as of September 18, 2024, by and between Perspective Therapeutics, Inc. and Comecer SpA, incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Company on September 20, 2024.

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MASTER EQUIPMENT AND SERVICES AGREEMENT THIS MASTER EQUIPMENT AND SERVICES AGREEMENT (“Agreement”) is dated effective as of September 18, 2024 (“Effective Date”) by and between P

Form of Statement of Work Pursuant to Master Equipment and Services Agreement, dated as of September 18, 2024, by and between Perspective Therapeutics, Inc. and Comecer SpA, incorporated by reference to Exhibit 10.2 to the Form 8-K filed by the Company on September 20, 2024.

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STATEMENT OF WORK NO. 1 PURSUANT TO MASTER EQUIPMENT AND SERVICES AGREEMENT This Statement of Work No. 1 (“SOW No. 1”) dated effective September 18, 2024, entered into by Perspec

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 05, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Exhibit 99.1 Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma SEATTLE – September 5, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Perspective Therapeutics, Inc.

As filed with the Securities and Exchange Commission on August 13, 2024

As filed with the Securities and Exchange Commission on August 13, 2024 Registration No.

Isoray, Inc. 2017 Equity Incentive Plan, incorporated by reference to Exhibit 10.2 on the Form 10-Q filed on August 13, 2024.

Exhibit 10.2 ISORAY, INC. 2017 EQUITY INCENTIVE PLAN (Conformed Version Reflecting Reverse Stock Split Effective June 14, 2024) 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the IsoRay, Inc. 2017 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable IsoRay, Inc., a Minnesota corporation (the “Company”), and any Affiliate to attract and retain the t

Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 of the Form 10-Q filed on August 13, 2024.

Exhibit 10.1 PERSPECTIVE THERAPEUTICS, INC. THIRD AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN (AMENDED AND RESTATED MAY 31, 2024) (Conformed Version Reflecting Reverse Stock Split Effective June 14, 2024) 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan (the “Plan”). The purposes of t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33407 PER

Corporate Presentation August 2024 NYSE: CATX

Corporate Presentation August 2024 NYSE: CATX Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com

Controlled Equity OfferingSM Sales Agreement, dated as of August 13, 2024, by and among Perspective Therapeutics, Inc., Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, incorporated by reference to Exhibit 1.1 of the Form 8-K filed on August 13, 2024.

Exhibit 1.1 Perspective Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement August 13, 2024 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 RBC Capital Markets, LLC 200 Vesey Street New York, NY 10281 Ladies and Gentlemen: Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Perspective Therapeutics, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com

Up to $250,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-279692 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2024) Up to $250,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”), dated as of August 13, 2024, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC (each, an “Agent” and, collectively, the “Agents”), relating to the sa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Com

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results • Completed enrollment of initial Cohort 2 patients in its VMT-α-NET and VMT01 clinical trials • On track to advance multiple pre-IND assets into the clinic in the next 12-18 months • Making continued progress on build out of manufacturing infrastructure • Cash, cash equivalents and short-term investments balance of approximately $293 million expected to be sufficient to fund our current planned operations and capital investments into mid-2026 SEATTLE – August 12, 2024 – Perspective Therapeutics, Inc.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials • Disclosed a new internally discovered molecule that targets fibroblast activation protein-α • Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sit

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (C

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Perspective Therapeutics, Inc., effective June 14, 2024, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on June 14, 2024.

Exhibit 3.1 ANNEX A Certificate of Amendment TO THE Amended and Restated Certificate of Incorporation of PERSPECTIVE THERAPEUTICS, Inc. Perspective Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is Perspective Therapeutics, In

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Exhibit 99.1 Perspective Therapeutics Announces 1-for-10 Reverse Stock Split SEATTLE, WASHINGTON – June 11, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will effect a 1-for-10 reverse stock split, effective at 4:0

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan.

Exhibit 10.1 ANNEX B perspective therapeutics, INC. THIRD AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN (EFFECTIVE May 31, 2024) 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Perspective Therapeutics, Inc. Third Amended and Restated 2020 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable Perspective Therapeutics, Inc., a Delaware corporati

Form of Pre-funded Warrant to Purchase Common Stock, incorporated by reference to Exhibit 4.1 of the Form 8-K filed on May 29, 2024.

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: [•], 2024 Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Exhibit 99.1 Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants SEATTLE, May 24, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwri

Underwriting Agreement, by and between Perspective Therapeutics, Inc. and BofA Securities, Inc., as representative of the underwriters named therein, dated May 24, 2024.

Exhibit 1.1 Perspective Therapeutics, Inc. 51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 24, 2024 Perspective Therapeutics, Inc. 51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock UNDERWRITING AGREEMENT May 24, 2024 BofA Securities, Inc. as Representative of the se

Filing Fee Table (filed herewith).

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Perspective Therapeutics, Inc.

Form of Indenture, incorporated by reference to Exhibit 4.6 of the Registrant Statement on Form S-3 filed on May 24, 2024.

Exhibit 4.6 INDENTURE DATED AS OF , 20 BETWEEN PERSPECTIVE THERAPETUICS, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series i TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions. 1 Section 1.02 Compliance Certificates and Opinions. 6 Section 1.03 Form of Documents Delivered to Trustee. 6 Section 1.04 A

Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock

Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated May 24, 2024 Relating to Prospectus Dated May 24, 2024 Registration Statement No.

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Perspective Therapeutics, Inc.

51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-279692 Prospectus Supplement (To prospectus dated May 24, 2024) 51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock We are offering 51,515,880 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,464,252 shares of our common stock pursuant

As filed with the Securities and Exchange Commission on May 24, 2024

As filed with the Securities and Exchange Commission on May 24, 2024 Registration No.

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

Exhibit 99.1 Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 SEATTLE, WASHINGTON – May 20, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Perspective Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-33407 (Commission File Number) 41-1458152 (IRS Employer Identification No.) 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 (Address of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY Report PURSUANT TO Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commis

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results • Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials • Disclosed a new internally discovered molecule that targets fibroblast activation protein-α • Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sit

CATX / Perspective Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

Unaudited Pro Forma Condensed Consolidated Financial Information

Unaudited Pro Forma Condensed Consolidated Financial Information Brachytherapy Asset Disposition On December 7, 2023, Isoray Medical, Inc.

148,352,336‬ Shares of Common Stock

Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-278362 PROSPECTUS 148,352,336‬ Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders named in this prospectus under the caption “Selling Stockholders,” of up to 148,352,336‬ shares of our common stock, par value $0.001 per share. We are not selling any shares of common sto

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 05, 2024 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

PERSPECTIVE THERAPEUTICS, INC. 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121

PERSPECTIVE THERAPEUTICS, INC. 2401 Elliott Avenue, Suite 320 Seattle, Washington 98121 April 8, 2024 VIA EDGAR Office of Industrial Applications and Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Conlon Danberg Re: Perspective Therapeutics, Inc. Registration Statement on Form S-3 Filed March 29, 2024 File No. 333-27

LETTER

United States securities and exchange commission logo April 8, 2024 Johan (Thijs) Spoor Chief Executive Officer Perspective Therapeutics, Inc.

Letter of Assure CPA, LLC, dated April 8, 2024, incorporated by reference to Exhibit 16.1 of the Form 8-K filed on April 8, 2024.

Exhibit 16.1 April 8, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated April 8, 2024, of Perspective Therapeutics, Inc. and are in agreement with the statements contained in the second, fourth, fifth, and sixth sentences therein. We have no basis to agree or disagree with other statements of the registrant conta

Amendment No. 1 to Asset Purchase Agreement, dated March 28, 2024, by and among Isoray Medical, Inc., GT Medical Technologies, Inc., and Perspective Therapeutics, Inc., incorporated by reference to Exhibit 2.1 of the Form 8-K filed on April 3, 2024.

Exhibit 2.1 CONFIDENTIAL AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this "Amendment”), dated as of March 28, 2024, is by and among Isoray Medical, Inc., a Delaware corporation (“Seller”), Perspective Therapeutics, Inc., a Delaware corporation (“Seller Parent”), and GT Medical Technologies, Inc., a Delaware corporation (“Buyer,” and together with S

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33407 (Commission File

Filing Fee Table.

Exhibit107 Calculation of Filing Fee Table Form S-8 (Form Type) Perspective Therapeutics, Inc.

As filed with the Securities and Exchange Commission on April 1, 2024

As filed with the Securities and Exchange Commission on April 1, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Perspective Therapeutics, Inc.

As filed with the Securities and Exchange Commission on March 29, 2024

Table of Contents As filed with the Securities and Exchange Commission on March 29, 2024 Registration No.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE – March 28, 2024 – Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results f

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33407 (Commission File

License Agreement, by and between Perspective Therapeutics, Inc. and Mayo Foundation for Medical Education and Research, dated December 31, 2023, incorporated by reference to Exhibit 10.28 of the Form 10-K filed on March 28, 2024.

Exhibit 10.28 Certain information has been excluded from this exhibit (indicated by “[***]”) because such information is both (i) not material and (ii) the type that the company treats as private or confidential. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH PATENT LICENSE AGREEMENT This patent license agreement (“Agreement”) is by and between Mayo Foundation for Medical Education and Researc

Subsidiaries of the Company.

Exhibit 21.1 Subsidiaries of the Company Isoray Medical, Inc., a Delaware corporation Isoray International, LLC, a Washington limited liability company Viewpoint Molecular Targeting, Inc. a Delaware corporation Perspective Therapeutics Pty Ltd, an Australian Company

Form of Indemnification Agreement, incorporated by reference to Exhibit 10.6 on the Form 10-K filed on March 28, 2024.

Exhibit 10.6 FORM OF INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20, but effective as of [●], between Perspective Therapeutics, Inc., a Delaware corporation (“Perspective” or the “Company”), and (“Indemnitee”). WHEREAS: 1. Highly competent persons have become more reluctant to serve corporations as directors and officers or in other c

Registration Rights Agreement, dated January 22, 2024, by and between the Company and Lantheus Alpha Therapy, LLC, incorporated by reference to Exhibit 10.26 of the Form 10-K filed on March 28, 2024.

Exhibit 10.26 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 22, 2024, between Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), and Lantheus Alpha Therapy, LLC, a Delaware limited liability company (the “Investor”). RECITALS This Agreement is made pursuant to the Investment Agreement, dated as of Jan

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Perspective Therapeutics, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K

Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-33407 Perspective

Incentive Compensation Recovery Policy, incorporated by reference to Exhibit 97 of the Form 10-K filed on March 28, 2024.

Exhibit 97 PERSPECTIVE THERAPEUTICS, INC. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Perspective Therapeutics, Inc. (the “Company”) on November 15, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Perspective Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2024 Perspective Therapeutics, Inc.

Corporate Presentation

Exhibit 99.2

Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

Exhibit 99.1 Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) - Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers througho

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 7, 2024 Perspective Therapeutics, Inc.

Corporate Presentation

Exhibit 99.1

CATX / Perspective Therapeutics, Inc. / Lantheus Holdings, Inc. - SC 13D/A Activist Investment

SC 13D/A 1 d749365dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 46489V104 (CUSIP Number) Lantheus Holdings, Inc. 201 Burlington Road, South Building Bedford, MA 01730 Att

Registration Rights Agreement, dated March 6, 2024, incorporated by reference to Exhibit 10.3 of the Form 8-K filed on March 6, 2024

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 6, 2024, among Perspective Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the several purchasers identified on Schedule 1 to the Investment Agreement (defined below) (each, an “Investor” and collectively, the “Investors”). RECITALS This Agree

Perspective Therapeutics Announces $87.4 Million Private Placement

Exhibit 99.1 Perspective Therapeutics Announces $87.4 Million Private Placement SEATTLE, WASHINGTON – March 4, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select gr

Investment Agreement, dated March 4, 2024, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on March 6, 2024.

Exhibit 10.1 INVESTMENT AGREEMENT This Investment Agreement (this “Agreement”), dated as of March 4, 2024, by and among Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal place of business at 2401 Elliott Avenue, Suite 320, Seattle, Washington 98121 and each purchaser identified on Schedule 1 hereto (each, an “Investor” and collectively, the “Investors”). Ca

Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility

Exhibit 99.2 Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility SEATTLE, WASHINGTON – March 05, 2024 – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art m

Placement Agency Agreement, dated March 4, 2024, by and among Perspective Therapeutics, Inc. and Oppenheimer & Co. Inc.

Exhibit 10.2 PLACEMENT AGENCY AGREEMENT March 4, 2024 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to issue and sell directly to various investors (each, an “Investor” and, collectively, the “Inve

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Commi

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 5, 2024 Perspective Therapeutics, Inc.

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

EX-99.7 5 d785059dex997.htm EX-99.7 EXHIBIT 99.7 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Perspective Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: February 1, 2024 LANTHEUS HOLDINGS, INC. By: /s/

Power of Attorney (Lantheus Alpha Therapy, LLC)

EX-99.6 4 d785059dex996.htm EX-99.6 EXHIBIT 99.6 POWER OF ATTORNEY Know all by these presents, that Lantheus Alpha Therapy, LLC (the “Company”) hereby constitutes and appoints each of Dan Niedzwiecki, Eric Green and Dustin Hawks of the Company and Jill Simon of Cooley LLP, signing singly, and with full power of substitution, the Company’s true and lawful attorneys-in-fact and agents to: (1) prepar

Power of Attorney (Lantheus Holdings, Inc.)

EX-99.5 3 d785059dex995.htm EX-99.5 Exhibit 99.5 POWER OF ATTORNEY Know all by these presents, that Lantheus Holdings, Inc. (the “Company”) hereby constitutes and appoints each of Dan Niedzwiecki, Eric Green and Dustin Hawks of the Company and Jill Simon of Cooley LLP, signing singly, and with full power of substitution, the Company’s true and lawful attorneys-in-fact and agents to: (1) prepare, e

Registration Rights Agreement between the Issuer and Lantheus Alpha Therapy, LLC, dated January 22, 2024.

EX-99.4 2 d785059dex994.htm EX-99.4 Exhibit 99.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 22, 2024, between Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), and Lantheus Alpha Therapy, LLC, a Delaware limited liability company (the “Investor”). RECITALS This Agreement is made pursuant to the In

CATX / Perspective Therapeutics, Inc. / Lantheus Holdings, Inc. - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 46489V104 (CUSIP Number) Lantheus Holdings, Inc. 201 Burlington Road, South Building Bedford, MA 01730 Attention: Daniel Niedzwiecki (978) 671-8001 (Name, A

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

Exhibit 99.3 Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement SEATTLE, January 22, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the closing of its previously

Perspective Therapeutics Announces Proposed Public Offering

Exhibit 99.1 Perspective Therapeutics Announces Proposed Public Offering SEATTLE, January 17, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has commenced an underwritten public offering of shares of its common stoc

Form of Pre-funded Warrant to Purchase Common Stock, incorporated by reference to Exhibit 4.1 of the Form 8-K filed on January 22, 2024.

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: [•], 2024 Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Perspective Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

Exhibit 99.2 Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement SEATTLE, January 18, 2024 – Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten

Underwriting Agreement, dated January 17, 2024, by and between Perspective Therapeutics, Inc. and Oppenheimer & Co. Inc

Exhibit 1.1 132,075,218 Shares of Common Stock Pre-Funded Warrants to Purchase 30,086,944 Shares of Common Stock Perspective Therapeutics, Inc. UNDERWRITING AGREEMENT January 17, 2024 Oppenheimer & Co. Inc. as Representative of the several Underwriters named in Schedule I hereto 85 Broad Street New York, NY 10004 Ladies and Gentlemen: Perspective Therapeutics, Inc., a Delaware corporation (the “Co

132,075,218 Shares of Common Stock Pre-Funded Warrants to Purchase 30,086,944 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-275638 Prospectus Supplement (To prospectus dated December 14, 2023) 132,075,218 Shares of Common Stock Pre-Funded Warrants to Purchase 30,086,944 Shares of Common Stock We are offering 132,075,218 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 30,086,944 shares of ou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 17, 2024 Perspective Therapeutics, Inc.

Asset Purchase Agreement, by and between Perspective Therapeutics, Inc. and Progenics Pharmaceuticals, Inc., dated January 8, 2024, incorporated by reference to Exhibit 10.2 of the Form 8-K/A filed on January 17, 2024.

Exhibit 10.2 Certain information has been excluded from this exhibit (indicated by “[***]”) because such information is both (i) not material and (ii) the type that the company treats as private or confidential. ASSET PURCHASE AGREEMENT by and between PROGENICS PHARMACEUTICALS, INC., as Seller, PERSPECTIVE THERAPEUTICS, INC., as Purchaser, AND For purposes of Section 9.12 only LANTHEUS MEDICAL IMA

SUBJECT TO COMPLETION, DATED JANUARY 17, 2024

Filed Pursuant to Rule 424(b)(5) Registration No. 333-275638 The information in this preliminary prospectus supplement is not complete and may be changed. The registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

Exhibit 99.1 Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01 SEATTLE – January 17, 2024 – Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical studies for both of its lead product candidates, [21

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Perspective Ther

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 Perspective Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33407 41-1458152 (State or Other Jurisdiction of Incorporation) (Co

Corporate Presentation

Exhibit 99.1